Cargando…

Biosimilars: To switch or not to switch – that is the question

Detalles Bibliográficos
Autor principal:	Szekanecz, Zoltán
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie 2020
Materias:	Editorial Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174792/ https://www.ncbi.nlm.nih.gov/pubmed/32322116 http://dx.doi.org/10.5114/reum.2020.93111

Ejemplares similares

Biosimilar switching – current state of knowledge
por: Wiland, Piotr, et al.
Publicado: (2018)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Commentary: What switch, to switch or not to switch: That is the question!
por: Kavarana, Minoo N.
Publicado: (2020)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

The Law and Ethics of Switching from Biologic to Biosimilar in Canada
por: Murdoch, Blake, et al.
Publicado: (2020)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Switching Between Epoetins: A Practice in Support of Biosimilar Use
por: D’Amore, Carmen, et al.
Publicado: (2016)

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
por: Peters, Bas J. M., et al.
Publicado: (2021)

Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
por: Cohen, Hillel P., et al.
Publicado: (2022)

The Psychological Risks Associated With the Non-medical Switch From Biologics to Biosimilars
por: Mazzoni, Davide, et al.
Publicado: (2021)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison
por: Baji, Petra, et al.
Publicado: (2014)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
por: Cohen, Hillel P., et al.
Publicado: (2018)

Switching from originator biological agents to biosimilars: what is the evidence and what are the issues?
por: Toussirot, Eric, et al.
Publicado: (2017)

Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab
por: Feagan, Brian G., et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa
por: Montero-Vilchez, Trinidad, et al.
Publicado: (2022)

Molecular switches and cages
por: Trauner, Dirk
Publicado: (2012)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review
por: Barbier, Liese, et al.
Publicado: (2020)

Comment on: “Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes”
por: Pires, Antonio, et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost‐effectiveness?
por: Roccuzzo, Gabriele, et al.
Publicado: (2022)

When aging switches on Alzheimer’s
por: Dong, Yue, et al.
Publicado: (2021)

The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
por: Panaccione, Remo
Publicado: (2021)

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics
por: Limdi, Jimmy K, et al.
Publicado: (2021)

The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence
por: Feagan, Brian G., et al.
Publicado: (2020)

Oncogene addiction: resetting the safety switch?
por: Li, Yulin, et al.
Publicado: (2014)

Switching gears for the sustainable development goals
Publicado: (2021)

Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: open‐label extension of the NOR‐SWITCH trial
por: Goll, G. L., et al.
Publicado: (2019)

Switching the Switch: Ligand Induced Disulfide Formation in HDAC8
por: Jänsch, Niklas, et al.
Publicado: (2020)

Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges
por: Oláh, Attila, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1lnu3onvskdodck2lq6sk281ub